🔴 Lantern Pharma is trading 11% down today after announcing a registered direct offering

Lantern Pharma is trading at $0.97, down 10.56%, following its September 29 announcement of a registered direct offering.

• The deal covers 3,669,725 shares at $1.09 each, plus warrants for up to 3,669,725 additional shares, creating potential dilution.
• It was expected to close around September 30. The S&P 500 and Nasdaq were higher, so broad-market weakness does not explain the decline; no separate September 30 catalyst was confirmed in the results.